• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $DERM

    Journey Medical Corporation

    Subscribe to $DERM
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation develops and commercializes pharmaceutical products for the treatment of dermatological conditions. It markets generic prescription drugs for dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: journeymedicalcorp.com

    Recent Analyst Ratings for Journey Medical Corporation

    DatePrice TargetRatingAnalyst
    8/22/2024$9.00Buy
    Rodman & Renshaw
    6/28/2024$11.00Buy
    ROTH MKM
    2/25/2022$9.00Overweight
    Cantor Fitzgerald
    12/16/2021$15.00Buy
    Roth Capital
    12/7/2021$14.00Buy
    B. Riley Securities
    See more ratings

    Journey Medical Corporation Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Journey Medical with a new price target

      Rodman & Renshaw initiated coverage of Journey Medical with a rating of Buy and set a new price target of $9.00

      8/22/24 7:21:37 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH MKM resumed coverage on Journey Medical with a new price target

      ROTH MKM resumed coverage of Journey Medical with a rating of Buy and set a new price target of $11.00

      6/28/24 7:38:15 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Journey Medical with a new price target

      Cantor Fitzgerald initiated coverage of Journey Medical with a rating of Overweight and set a new price target of $9.00

      2/25/22 9:05:17 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital initiated coverage on Journey Medical with a new price target

      Roth Capital initiated coverage of Journey Medical with a rating of Buy and set a new price target of $15.00

      12/16/21 6:55:51 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities initiated coverage on Journey Medical with a new price target

      B. Riley Securities initiated coverage of Journey Medical with a rating of Buy and set a new price target of $14.00

      12/7/21 6:10:10 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Journey Medical Corporation Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Maraoui Claude sold $33,065 worth of shares (4,834 units at $6.84), decreasing direct ownership by 0.21% to 2,348,313 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      5/5/25 5:34:52 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Benesch Joseph sold $16,478 worth of shares (2,409 units at $6.84), decreasing direct ownership by 1% to 203,557 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      5/5/25 5:34:22 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • COO Alloush Ramsey sold $19,542 worth of shares (2,857 units at $6.84), decreasing direct ownership by 0.56% to 504,817 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      5/5/25 5:31:11 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Maraoui Claude was granted 350,000 shares, increasing direct ownership by 17% to 2,353,147 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      4/16/25 7:07:59 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Benesch Joseph was granted 160,000 shares, increasing direct ownership by 348% to 205,966 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      4/16/25 7:06:23 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Alloush Ramsey claimed ownership of 507,674 shares (SEC Form 3)

      3 - Journey Medical Corp (0001867066) (Issuer)

      4/4/25 4:05:14 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Maraoui Claude sold $246,848 worth of shares (49,271 units at $5.01), decreasing direct ownership by 2% to 2,003,147 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      3/11/25 7:53:02 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Maraoui Claude sold $203,451 worth of shares (40,456 units at $5.03), decreasing direct ownership by 2% to 2,052,418 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      3/10/25 6:21:57 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Maraoui Claude sold $360,762 worth of shares (70,556 units at $5.11), decreasing direct ownership by 3% to 2,092,874 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      3/5/25 7:53:31 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Benesch Joseph sold $7,084 worth of shares (1,365 units at $5.19), decreasing direct ownership by 3% to 45,966 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      2/24/25 4:01:12 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care